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Invasive  fungal  infections  (IFI)  are  an
important cause of morbidity, increased hospi-
talization and healthcare costs in critically ill or
immunocompromised  children.  The  mortality
is comprised between 5 and 20%. In the last 2
decades, the epidemiology of candidemia has
changed with an increase of episodes caused
by  non-Candida  albicans species.  Central
venous catheter, diagnosis of malignancy, and
receipt of either vancomycin or antimicrobials
with activity against anaerobic organisms for
>3 days have been associated with the develop-
ment of candidemia in the pediatric intensive
care unit (PICU). Additional risk factors found
in hematological patients were the diagnosis of
aplastic anemia, performing an unrelated bone
marrow  or  cord  blood  transplant,  the  occur-
rence of a graft versus host disease and the use
of steroids. Early antifungal treatment is rec-
ommended to reduce mortality. In neutropenic
patients,  liposomal  amphotericin  B,  an
echinocandin (caspofungin, micafungin), and
voriconazole  are  considered  the  best  option
especially  for  C.  glabrata and  C.  krusei.
Fluconazole remains a valid option for infection
by Candida albicans in patients not exposed to
fluconazole prophylaxis. Amphotericn B deoxy-
cholate is generally not recommended because
of its nephrotoxicity. 
Epidemiology
Invasive fungal infections (IFI) are a consid-
erable source of morbidity, mortality, increased
hospitalization, and high healthcare costs in
critically ill or immunocompromised children.1
Overall the incidence of sepsis due to fungal
organisms increased by 207% in the last 20
years,2 with a similar trend in pediatric and
adult patients.1 In children, Candida spp. rep-
resent  the  more  frequent  etiologic  agent  of
sepsis by fungi.1 In a prospective study of pedi-
atric  nosocomial  bloodstream  infections
(BSIs), Candida spp. were the third most com-
mon microbial cause of BSIs overall (9.4% of
isolates), and the most common fungal cause.3
The incidence of candidemia varies greatly
between populations, with an incidence of 1.9 to
10.0 per 100,000 subjects reported in different
population surveillance studies.4,5 Candidemia
affects especially the neonatal than adults and
older children and is frequently associated with
signs and symptoms of sepsis syndrome.
The epidemiology of candidemia is changing
with an increase in the proportion of episodes
caused by non-Candida albicans species. This,
in part, has been attributed to the broad use of
azole as prophylaxis and therapy.6
The  attributable  mortality  and  morbidity
associated with hospitalization remain signifi-
cant (10.0%-14.5%) in all age groups despite
therapeutic advances.1 Watson and coworkers
reported  that  fungal  sepsis  was  associated
with the second highest case fatality (13.0%)
in children older than 1 year and up to 19 years
old in 1995, just behind pneumococcal sepsis
(14.5%).7 The rate was higher in children aged
1 to 10 years (16.8%) or 11 to 19 years (11.6%)
than in those younger than 1 year (10.8%).
Zaoutis and colleagues, in a large USA data-
bases  for  adult  (n=8949)  and  pediatric
(n=1118)  hospitalized  patients,  found  that
pediatric patients (median age 1 year, range 0-
7) with a diagnosis of candidemia had a 10%
higher  rate  of  mortality  (95%  CI=6.2-13.8)
compared  with  matched  candidemia-unex-
posed hospitalized patients.1 Data on the epi-
demiology and on the outcome of invasive fun-
gal infections and candidemia in children with
cancer are limited. Few studies have been con-
ducted, often limited to patients with leukemia
or HSCT. The incidence of IFI in this set of
patients  varies  between  4,9%  to  13,6%  with
mortality rate ranging from a minimum of 5%
in patients with ALL8 to 59%.9 In a prospective
multicenter  study  in  pediatric  patients  with
cancer o after HSCT, Castagnola et al. reported
an overall mortality of 28% for all causes of IFI
and of 5% for fungemia (mostly of them were
candidemia).10 In the most recent and largest
series, Mor et al. found an IFI and candidemia
incidence respectively of 7,2% and 1,4% in a
population of 1047 children with hematological
and oncologic disease or HSCT, and a mortali-
ty rate of 21,7%.11
Risk factors and prognosis
Risk factors for fungal infection are similar
in pediatric and adult patients. They include
prolonged stay in an ICU, prior bacterial infec-
tion, use of a central venous line (CVC), total
parenteral  nutrition  (hyperalimentation),
immunosuppression  (related  to  malignancy
and  its  treatment,  transplantation  immuno-
suppressive  therapy  or  other  factors).
Additional factors associated with elevated risk
of invasive candidiasis are the use of mechan-
ical  ventilation  (endotracheal  intubation),
dialysis, extended vancomycin use, and recent
surgery.12 Children  suffering  from  acute
myeloid leukemia or relapsed leukemia or sub-
mitted to HSCT are at high risk for IFI. For
pediatric  patients  receiving  HSCT  additional
risk factors are represented by aplastic ane-
mia,  unrelated  bone  marrow  or  cord  blood
transplantation, graft versus host disease and
steroid use.13Zaoutis et al.found that the pres-
ence of a CVC, a diagnosis of malignancy, and
receipt of either vancomycin or antimicrobials
with activity against anaerobic organisms for
>3 days were independently associated with
the development of candidemia in the PICU.
Children in the PICU with ≥3 of these risk fac-
tors  in  different  combinations  had  between
10% and 46% predicted probability of develop-
ing candidemia.14In particular, the presence of
a vascular access device or CVC seems to be
one  of  the  most  important  risk  factor:  can-
didemia may be associated to a vascular access
device  even  in  70%  of  infected  children.15
However, the source of Candida in a particular
subgroup of patients suffering from neoplastic
disease, more likely derives from the gastroin-
testinal tract due to mucosal disruption caused
by cytotoxic chemotherapy and abrogation of
normal gastrointestinal flora by antimicrobial
therapy,  which  create  a  permissive  environ-
ment that allows Candida to invade the mesen-
teric  circulation.  Candida infection  can  dis-
seminate  to  end  organs,  including  brain,
lungs, liver, heart, kidneys, eyes, and spleen.
Disseminated disease is associated with high-
er  candidemia-related  mortality.  Risk  factors
for dissemination in a children with persistent
candidemia are represented by CVC in place
and immunosuppression. 
In a recent study on epidemiology and out-
come of candidemia in USA, it resulted that C.
Pediatric Reports 2012; volume 4:e9
Correspondence:  Simone  Cesaro,  Pediatric
Hematology  Oncology,  Azienda  Ospedaliera
Universitaria  Integrata,  piazzale  L.A.  Scuro  10,
37134 Verona, Italy.
Tel. +39.045.8126889 - Fax: +39.045.8124909.
E-mail: simone.cesaro@ospedaleuniverona.it
Key words: candidemia, Candida spp. Sepsis.
Received for publication: 14 October 2011.
Revision received: 9 January 2012.
Accepted for publication: 10 January 2012.
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright C. Cugno and S. Cesaro., 2012
Licensee PAGEPress srl, Italy
Pediatric Reports 2012; 4:e9
doi:10.4081/pr.2012.e9[Pediatric Reports 2012; 4:e9] [page 31]
Albicans was detected in 45,6% of cases and
that among C. non albicans (54,4% of cases)
the majority of species indentified included C.
glabrata (26%),  C.  parapsilosis (15,7%),  C.
tropicalis (8,1%) and C. krusei (2,5%).16
Patients with C. glabrata and C. krusei can-
didemia were the most likely to have received
prior  antifungal  therapy.  This  may  reflect
selective pressure caused by the extensive use
of  prophylactic  fluconazole  in  susceptible
hosts. Patients with C. krusei candidemia were
younger and did not generally have such addi-
tional  risk  factors  as  parenteral  nutrition,
mechanical ventilation and concomitant bacte-
rial infections.16 C. parapsilosis is a common
pathogen in neonates and children.15 The inci-
dence of C. parapsilosis infections has been
attributed, in part, to the association among C.
parapsilosis, catheter infection, and parenteral
nutrition, because of its strong affinity for for-
eign material and its growth advantage in total
parenteral nutrition solution. Transmission of
C. parapsilosis from the hands of health care
workers  to  neonates  and  children  has  been
suggested as a contributor, because the organ-
ism  is  commonly  carried  on  the  hands  of
health care workers. 
In  both  adult  and  pediatric  patients,  can-
didemia  due  to  C.  parapsilosis is  associated
with lower mortality rates than cases involving
C.  albicans,  whereas  crude  mortality  rates
seem to be generally lower in pediatric than
adult patients with candidemia regardless of
the Candida spp. involved.17
Diagnosis
Blood culture is the current gold standard
for diagnosis of candidemia, although it is slow
and lacks of sensitivity. Other tests, based on
non-culture-based methods, such as mannan
antigen and anti-mannan antibodies, may be
useful  for  diagnosing  invasive  candidiasis.18
Patients with persistent positivity of blood cul-
tures by Candida should be clinically assessed
to  exclude  end-organ  Candida diseases  by
ultrasound  of  liver,  spleen,  and  heart,  fun-
doscopy  (eye)  and  if  needed,  by  computed
tomography or magnetic resonance. 
Therapy
The outcome of candidemia largely depends
on the early initiation of effective antifungal
therapy.19 Inadequate initial therapy is associ-
ated with a significant increase in mortality.
Delaying the initiation of antifungal therapy
for more than 12 hours after withdrawal of the
blood sample that yields Candida spp. may dou-
ble the mortality compared to an earlier start of
therapy. The decisional process for the treat-
ment usually takes place in two steps: the first
treatment is based on the positivity of blood
culture for Candida spp. before species identi-
fication  and  may  be  subsequently  modified
according to identification of species and to
their susceptibility profile.
Fluconazole, Amphotericin B deoxycholate,
caspofungin  and  voriconazole  are  primary
treatment  options  in  non-neutropenic
patients, as demonstrated in many randomized
studies.20-22 On the other hand, only few data
are available on neutropenic patients.
Since its introduction in the early 1990s, flu-
conazole  has  been  established  as  the  most
commonly  used  drug  for  invasive  Candida
infections.  Amphotericin  B  preparations,
caspofungin  and  voriconazole  are  primarily
used for the treatment of patients with non-
albicans Candida infection  and⁄or  patients
with an increased risk for mould infections,
such  as  haematological  patients  receiving
immunosuppressive  therapy  or  transplant
recipients.  The  echinocandins  represent  the
latest class of systemically active antifungals.
They inhibit the synthesis of 1,3-beta-D-glu-
can, a key component of the fungal cell wall.
Caspofungin was the first echinocandin to be
approved by the FDA and the EMEA in 2001, fol-
lowed by anidulafungin (2007) and micafun-
gin (2008). As judged by randomized studies
and pharmacological profiles, these drugs are
valuable therapeutic options for invasive can-
didiasis. Caspofungin and micafungin are the
2  echinocandins  approved  for  pediatric
patients  with  invasive  candidiasis.23,24 They
have been studied in children with invasive
candidiasis.  Published  caspofungin  data  are
mostly  limited  to  neonatal  candidiasis,25
although its use in management of invasive
candidiasis was retrospectively described with-
in larger pediatric cohort studies.26,27
Efficacy  and  safety  of  the  echinocandins
were investigated in randomised, double blind-
ed clinical trials in patients with candidemia
and  other  forms  of  invasive  Candida infec-
tions.  Rex  et  al  in  a  randomized  study  per-
formed in early 90’, established the equivalent
efficacy of amphotericin B and fluconazole.21
On these basis, micafungin and caspofungin
has  been  tested  in  comparative  randomised
trial with liposomal amphotericin B, although
liposomal amphotericin B is not approved as
first-line treatment of invasive Candida infec-
tions. These studies established the non-infe-
riority of micafungin and caspofungin to stan-
dard  regimens.22,28-30 Caspofungin  was  as
effective as amphotericin B, and the efficacy of
micafungin  was  comparable  with  liposomal
amphotericin B and caspofungin. In addition
significantly less adverse effects occurred in
the echinocandin arms compared with ampho-
tericin  B  formulations.  Micafungin  also
demonstrated to be safe and effective in ran-
domized,  double-blind,  comparison  trial  in
children with invasive candidiasis and in an
open-label,  noncomparative  trial  for  newly
diagnosed  or  refractory  candidiasis.31,32 The
randomised trial of anidulafungin vs flucona-
zole was the first to demonstrate the superior-
ity of an antifungal drug vs a standard thera-
peutic regimen in invasive Candida infections,
with, in addition, a safer profile in terms of
hepatic toxicity.32 Echinocandins rarely inter-
act with other compounds and their applica-
tion is not affected by renal function, while
hepatic insufficiency requires moderate dose
adjustment only with caspofungin. Therefore
echinocandins may represent the treatment of
choice for intensive care patients, who usually
suffer from multiple organ failure and receive
broad  concomitant  medication  with  complex
drug-drug interactions. Among the echinocan-
dins, anidulafungin, which is not licensed for
the  pediatric  use,  appears  to  have  the  least
propensity of drug interactions and does not
require any dose adjustments. It thus may con-
fer an additional benefit in patients receiving
immunosuppressants  or  inducers  of  hepatic
metabolism and those with liver insufficiency.
In  Table  1  the  pediatric  dosages  and  the
grade  of  recommendation  for  neutropenic
patients  is  showed.  The  2009  guidelines  for
candidiasis management from the Infectious
Diseases  Society  of  America  (IDSA)  recom-
mended the empiric treatment for critically ill
patients with risk factors for invasive candidi-
asis  and  no  other  known  cause  of  fever.
Fluconazole or an echinocandin are the drugs
of  choice.33 An  echinocandin  or  liposomal
amphotericin B is preferred in most of neu-
tropenic patients with recent exposure to flu-
conazole or at high risk of infection due to
Candida glabrata or Candida krusei, resistant
to  azole.  Moreover  fluconazole  shows  less
activity against C. glabrata or C. krusei than
against other Candida spp. Voriconazole can be
used in situations in which additional cover-
age for mold is desired.33
Guidelines provided by the third European
Conference of Infections in Leukemia (ECIL 3)
recommended  the  use  of  liposomal  ampho-
tericin B, caspofungin or voriconazole in neu-
tropenic patients before species identification,
whereas fluconazole should not be used due to
prior exposure to fluconazole as prophylaxis.
Amphotericin B deoxycholate is generally not
recommended in hematological patients as the
concomitant use of nephrotoxic drugs or renal
impairment  is  more  frequent.  After  species
identification,  caspofungin  and  liposomal
amphotericin  B  are  considered  the  primary
choice  for  C.  glabrata and  C.  krusei while
voriconazole may be considered an alternative
treatment.34ECIL 3 also recommends to contin-
ue antifungal therapy for candidemia in neu-
tropenic host at least for 14 days after the last
positive blood culture, resolution of signs and
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symptoms  and  resolved  neutropenia.34 The
strong  recommendation  to  remove  central
venous  line  in  non-hematological  patients,
loses  out  in  neutropenic  patients  in  which
catheter  removal  often  creates  substantial
intravenous  access  difficulties.  However
experts’  opinion  is  that  catheter  should  be
removed when it is possible. On the other hand,
removal of central venous line is always recom-
mended when C. parapsilosis is isolated.34
In conclusion, the medical treatment of can-
didemia is changed in the last 2 decades with
the introduction of safe and broad-spectrum
antifungal  drugs.  This  allows  to  adjust  the
antifungal therapy on the basis of patient clin-
ical conditions and comorbidity, previous his-
tory of antifungal prohylaxis, and empirical or
target  use  of  antifungals.  More  studies  are
needed in the pediatric setting to tailor the
therapy not only on epidemiology and risk fac-
tors, but also on pharmacokinetic properties of
new molecules. 
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